New England Journal of Medicine
February 10, 2022 Vol. 386 No. 6
https://www.nejm.org/toc/nejm/medical-journal

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico L.M. Dunkle and Others
NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America.